Jamaica
Key Insights
- 1
No psilocybin therapy is approved for Jamaican patients; access is limited to retreats and research, with no formal decriminalisation framework.
- 2
Blossom shows 1 clinical trial in Jamaica, 0 active, studying psilocybin against placebo, with just 1 research organisation on file.
- 3
Jamaica became a global psilocybin outlier by allowing legal mushroom retreats from 2014, long before most jurisdictions moved.
- 4
Momentum is being driven by Rose Hill and UWI-linked research, including Jamaica’s first GMP-certified psilocybin lab and 2025 export activity.
Reimbursed Care Access
Jamaica is widely known for a permissive stance toward psilocybin-containing mushrooms (they are not scheduled under Jamaican law) and hosts commercial retreats and producers. Other classical and synthetic psychedelics (MDMA, DMT, 5‑MeO‑DMT, mescaline, 2C‑X) fall under Jamaica’s general Dangerous Drugs regulatory framework and are treated as controlled/illegal except insofar as they are used in approved clinical research. Ketamine is used in Jamaica as an established anesthetic in healthcare settings and can be prescribed; however, licensed esketamine (Spravato) does not appear to have a public national reimbursement pathway and psychedelic-assisted indications are confined largely to private/clinical‑trial settings.
Quick Indicators
Organizations
12Atman Retreats
Jamaica
Beckley Retreats
Jamaica
Equanimity
Jamaica
Evolution Retreats
Jamaica
Gaia Sagrada Retreat
Jamaica
Mycelia
Jamaica
MycoMeditations
Jamaica
ONE Psilocybin Retreats
Jamaica
Professor Roger Gibson Section of Psychiatry Faculty of Medical Sciences UWI
Jamaica
Silo Wellness
Jamaica
Wake
Jamaica
Zion Life Retreat
Jamaica
Clinical Trials
Active and completed clinical trials investigating psychedelic-assisted therapies in Jamaica.